Background: The overall 5-year survival rate for cervical cancer (CC) is low if diagnosed at an advanced stage, making it one of the most lethal cancers in the world. To this end, the World Health Organization has developed the 90-70-90 global strategy to eliminate CC in the coming Years (1). The search for new diagnostic and prognostic genetic signatures is essential in this fight. Objective: This study aims to identify potential biomarkers associated with metastasis and epithelial-mesenchymal transition (EMT) in CC. Methods: RNA sequencing of non-stem cancer cells (NSCCs) was performed, and adapters and low-quality sequences were trimmed. Then, the mapping reads, transcript, gene, and miRNA quantification, as well as the quantification of differentially expressed genes (DEGs), transcripts (DETs), and miRNAs (DEmiRNAs), were performed. Only genes and transcripts with significant expression profiles between 13 metastatic patients (M) and 8 with primary tumors (P) were selected. Finally, DEmiRNAs were chosen to target DEGs or DETs. The influence on overall survival of the patients was calculated by Kaplan-Meier (KM) analysis. Results: 9444 DETs, 2648 DEGs, and 178 DEmiRNAs were found, and these 16 DETs and 7 DEGs showed a strong regulation profile in groups. However, TCL6-206, LRRC1, and UBE2E1-AS1 were only overexpressed in the M patients. Similarly, in the literature, the lncRNA UBE2R2-AS1 and the gene UBE2E2 enhanced EMT in prostate and ovarian cancer (2), respectively, and the UBE2E1-AS1 was upregulated as a risky gene (HR>1) in the KM analysis. On the other hand, the LRRC1 (3) and TLC6-206 (4) were tumor suppressors in many cancers and, when overexpressed, increased the OS in the CC. Of 178 DEmiRNAs, LRRC1 was the target only from miR-222-5p. Conclusion: This is the first report about the association between TCL6-206 splice variant upregulation and metastasis, unlike your gene in the literature. Furthermore, the first study demonstrated an oncogenic role for LRRC1 as a potential target gene of this lncRNA and UBE2E1-AS1, with miR-222-5p identified as a potential competitive endogenous RNA (ceRNA).